OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Antibodies to watch in 2022	238
Antibodies to watch in 2021	235
Antibodies to watch in 2023	114
Targeting cancer with antibody-drug conjugates: Promises and challenges	87
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	58
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	53
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	51
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	49
Developments and opportunities in continuous biopharmaceutical manufacturing	40
In silico proof of principle of machine learning-based antibody design at unconstrained scale	37
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	37
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	36
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	36
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	34
Coming together at the hinges: Therapeutic prospects of IgG3	34
A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	32
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	32
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	31
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	31
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	31
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	30
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	29
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	28
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	27
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies	27

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	26
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	26
Impact of IgG subclass on molecular properties of monoclonal antibodies	25
Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope	25
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2	24
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody	24
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	24
Highly sensitive detection of antibody nonspecific interactions using flow cytometry	23
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis	22
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	21
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics	21
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	20
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV	20
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	20
Assessing developability early in the discovery process for novel biologics	20
Data mining patented antibody sequences	20
A non-clinical comparative study of IL-23 antibodies in psoriasis	19
Current strategies for detecting functional convergence across B-cell receptor repertoires	19
Enhancing the multi-attribute method through an automated and high-throughput sample preparation	19
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models	18
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies	18
Ensembles in solution as a new paradigm for antibody structure prediction and design	18
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo	17
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings	17
Predicting antibody binders and generating synthetic antibodies using deep learning	17
In silico prediction of post-translational modifications in therapeutic antibodies	17
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities	17
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters	17
Versatile and rapid microfluidics-assisted antibody discovery	17
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	16
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	16
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice	16
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	15
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein	15
Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics	15
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	14
Challenges in antibody structure prediction	14
Development of QSAR models for in silico screening of antibody solubility	14
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions	14
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	14
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL	14
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	14
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	14
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies	14
Protective antibodies against human parainfluenza virus type 3 infection	14
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351	13
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	13
Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties	13
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics	13
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention	12

Stability of a high-concentration monoclonal antibody solution produced by liquid–liquid phase separation	12
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	12
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	12
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	12
Animal- versus in vitro-derived antibodies: avoiding the extremes	12
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells	12
Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion	12
Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments	12